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Abstract. Alzheimer’s disease (AD) is a neurodegenerative disorder clinically characterized by cognitive deficit with progressive
worsening of memory. Recent data indicate that neurons, as well as other brain cells, can express enzymes such as cyclooxygenases
(COXs) and 5-lipoxygenase (5-LO) which are considered important in inflammatory cells. Moreover, it has been demonstrated
that COX-2 and 5-LO enzymes play a considerable role in the pathophysiology of AD. In order to assess the possible role
of COX-2 and 5-LO single nucleotide polymorphisms (SNPs) in AD, we examined their distribution in 341 AD patients and
190 controls from Northern Italy. A significant difference was observed in the distribution of the −765G COX-2 and −1708A
5-LO alleles between AD cases and controls (p = 0.03 for −765G/C COX-2 SNP; and p = 0.007 for −1708G/A 5-LO SNP).
Hence, COX-2 −765G and 5-LO −1708A alleles were overrepresented in AD patients and underrepresented in controls. Our
data suggest that these alleles of COX-2 and 5-LO could be risk factors for AD. These results seem of some importance for a
pharmacogenomic approach.
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INTRODUCTION
Inflammation clearly occurs in the brain of Alzhei-
mer’s disease (AD) patients and the classical media-
tors of inflammation, eicosanoids and cytokines, con-
tribute to the neurodegeneration [1–3]. Recent data in-
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dicate that neurons can also express enzymes such as
cyclooxygenases (COXs) and 5-lipoxygenase (5-LO)
which typically are considered important in inflamma-
tory cells [4,5]. The cyclooxygenases (COX-1, COX-
2) are the key enzymes in the conversion of arachidon-
ic acid to the precursors of bioactive lipid mediators,
eicosanoids, including prostaglandin (PG), thrombox-
ane, and prostacyclin [6]. COX-2 inducible enzyme
is widely expressed in the AD patient brain and its
expression correlates with amyloid plaque density and
neurofibrillary tangles [4,7–10]. In particular, COX-2
is expressed primarily in neurons, and possibly in oth-
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er brain cells under certain circumstances during the
clinical progression of the disease [11]. One possi-
ble mechanism of increased COX-2 gene expression
in the brain may involve the inflammation-related tran-
scription factor, NFκB; there is a strong correlation be-
tween NFκB DNA binding and COX-2 mRNA expres-
sion in AD brain [12]. Moreover, the COX-2 promoter
possesses multiple recognition sites specific for NFκB
DNA binding [13].
Additionally, several epidemiological studies have
suggested that long-term treatment with non-steroidal
anti-inflammatory drugs (NSAIDs), which include
COX-2 inhibitors, may reduce the risk of developing
AD [4,14–17]. On the other hand, a recent report based
on a longitudinal study of men and women aged 70
years and older with a family history of AD (ADAPT
study) showed that use of naproxen or celecoxib did
not improve cognitive function [18]. However, several
critical issues have been raised concerning the study
results, i.e., it has been claimed that the ADAPT study
does not indicate that NSAIDs, if taken during adult-
hood and for an extended period, cannot prevent or
delay the onset of dementia [19].
Non-mutually exclusive hypotheses on the role of
COX-2 in AD concern its possible influence on process-
ing of the amyloid-β protein precursor through a PG-
E2-mediated stimulation of γ-secretase activity [20].
In addition, COX-2 protein and PG-E2 concentrations
were selectively increased> 2-fold in the cerebral cor-
tex of subjects with the presenilin-2 (PS2) familiar
AD mutation relative to wild-type PS2 AD cases [21].
Moreover, it has been found that neuronal overexpres-
sion of human COX-2 in transgenic mice stimulated
excitotoxicity in vivo and in vitro. In particular, the re-
sults indicate that human COX-2 overexpressioncauses
neuronal cell cycle deregulation in the brain [22].
Hence, the use of NSAIDs, which block the synthesis
of eicosanoids, might interfere with the mechanisms
involved in the pathophysiology of AD, whether or not
dependent on inflammatory responses [4,14,15,17,20–
22].
A number of single nucleotide polymorphisms
(SNPs) have been described in the promoter region of
the COX-2 gene that probably regulates its transcrip-
tion. But only one polymorphism located at position
−765, a putative stimulatory protein-1 binding site, has
been shown to be functional. It has been shown that
the −765 CC genotype resulted in a reduction of ap-
proximately 30% in in vitro promoter activity and was
associated with lower plasma levels of inflammatory
markers, such as C-reactive protein [23].
In a previous study, this SNP was found to be asso-
ciated with reduced risk of AD [24]. That study report-
ed a significantly different distribution, in patients and
controls, of the −765 SNP whose G allele was under-
represented in control subjects and overrepresented in
patients with AD [24]. Recently, a study in the Chinese
population has demonstrated a significant association
between the polymorphisms of COX-2 and AD. How-
ever, they showed that carriers of +837 T allele in the
exon 10 had a 1.5-fold increase in the risk of AD [25].
An alternative pathway of arachidonic acid generates
leukotrienes (LTs), through the action of 5-LO togeth-
er with the 5-lipoxygenase-activating protein (FLAP).
LTs are implicated in a wide variety of inflammatory
disorders, including the chronic ones [26]. 5-LO has
also been described in neurons and in some glial cells
throughout the cerebrum, basal ganglia, and hippocam-
pus [5,27,28]. Compared to controls, a significant in-
crease of LTs was observed in cerebrospinal fluid from
AD and mild cognitive impairment patients. So the
activation of this enzyme occurs early in the course of
AD, before the onset of overt dementia, thereby impli-
cating its metabolites in the pathophysiology of AD [5,
27,28].
Several SNPs of these enzymes have been de-
scribed [29,30]. In particular, the −1708GA and
−1761GA SNPs in promoter region of 5-LO gene
and −336GA in promoter region of FLAP have been
claimed able to modify 5-LO/FLAP gene transcription
or the putative protein derived from translation of 5-
LO/FLAP mRNA [29]. Most studies have analyzed
these SNPs in association with asthma susceptibili-
ty [29,30]. Only a few genetic studies have identified
variants of the 5-LO gene and the FLAP gene promot-
er as risk factors in atherosclerosis and myocardial in-
farction [31,32]. These studies have shown that 5-LO
polymorphisms, involved in a decreased expression of
5-LO, are less represented in patients with myocardial
infarction and severe atherosclerosis [31,32].
Accordingly, it has been suggested that the polymor-
phisms putatively involved in a decreased expression
of 5-LO are underrepresented in AD patients. But an
overexpressed 5-LO gene could significantly increase
the brain’s vulnerability to neurodegeneration [27].
Since few studies have investigated the role of these
COX-2 and 5-LO polymorphisms in relation to AD [24,
25,27], we have evaluated whether these COX-2 and
5-LO SNPs can be considered risk factors for AD. If
responsible for a differential production of the relevant
enzymes, these SNPs could be involved in the patho-
physiology of AD.
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MATERIALS AND METHODS
Subjects
Diagnosis of probable AD was according to standard
clinical procedures and followed the NINCDS/ADRDA
and DSM-III-R criteria [33,34]. Cognitive perfor-
mance and alterations were measured according to the
Mini-Mental State Evaluation and the global deterio-
ration scale. All AD cases were defined as sporadic
because their family history did not mention any first-
degree relative with dementia. In addition, 80% of AD
patients showed clinical onset of the disease after 65
years of age (late-onset AD, LOAD), and 20% before
this age (early-onset AD, EOAD). The population of
AD consisted of 341 patients from Northern Italy with
clinical diagnosis of probable AD (238 women and 103
men; age range: 53–98 years; mean age: 74.88± 8.44).
AD patients included in the study did not present major
co-morbidity such as cancer, symptomatic (present or
previous) cardiovascular diseases, and major inflam-
matory diseases as autoimmunity and infections. Con-
trols were 190 unrelated individuals (100 women and
90 men; age range: 65–93; mean age 73.21± 8.24) ran-
domly selected from a retirement home. These subjects
were checked and judged to be in good health based
on their clinical history and on blood tests (complete
blood cell count, erythrocyte sedimentation rate, glu-
cose, urea nitrogen, creatinine, electrolytes, C reactive
protein, liver function tests, iron, proteins, cholesterol,
and triglycerides). The controls were collected from
the same population as the patient cohort. Patients and
controls were assessed to have parents and grandpar-
ents born in Northern Italy to ensure ethnicity. Con-
sequently, possible confounding effects, like the inclu-
sion in the study of members of different ethnic groups,
have been minimized. Informed consent was obtained
from all guardians of patients and controls according
to Italian law.
Molecular methods
The salting-out method was used to extract the DNA,
following the standard protocol [35]. DNA was ex-
tracted and genotyped for 765 G/C COX-2,−1708 G/A
and −1761 G/A 5-LO, −336 G/A FLAP SNPs, and
ApoE4 polymorphism by using a polymerase chain re-
action [32,36].
Statistical information
The data were tested by χ2 test for the goodness of
fit between the observed and expected genotype fre-
quencies according to the Hardy-Weinberg equilibrium
(HWE). Differences in allele and genotypic frequencies
of the different SNPs among the groups were evaluated
by gene count and χ2 test with Yate’s correction. Odd
ratio (OR) with confidence interval (CI) was also calcu-
lated. It might be argued that a Bonferroni-type adjust-
ment should be performed to correct for the testing of
multiple polymorphisms. However, this correction is
too stringent and has the potential to ignore important
observations [37,38], hence we did not carry out this
correction. In patients and controls, a logistic regres-
sion analysis was used to investigate the associations of
genotypes with AD, after adjustment for ApoE4 allele,
gender, and age at onset (LOAD vs. EOAD). The OR
(with CI) was calculated as exponential of regression
coefficient and its standard error.
Power estimates were calculated with PS software, v.
2.1.31. Briefly, power was estimated using the number
of cases and controls and the prevalence of the putative
susceptibility allele or genotype in the control popula-
tion [39]. The average power across individual SNPs
was 0.45, which is higher than most AD association
studies [1,40].
RESULTS
The frequencies of the genotypes of all SNPs under
investigation, in AD patients and age-related controls
from Northern Italy, were in HWE. Table 1 shows the
genotype and allele frequencies of the different SNPs
of COX-2, 5-LO, and FLAP genes in AD patients and
controls.
The distribution of COX-2 genotypes between AD
patients and controls was significantly different. Sub-
jects with the−765GG genotype of COX-2 were over-
represented among AD patients and underrepresented
in age-related controls. According to genotype, a sig-
nificant difference in the G allele frequency between
AD patients and controls was observed. The G allele
frequency was found to be higher in patients than in
controls.
Concerning the genotype and allele frequencies of
5-LO and FLAP polymorphisms, there was a signif-
icant difference between AD patients and age-related
controls for 5-LO −1078 SNP. In fact, the 1708AA
genotype was overrepresented among AD patients and
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Table 1
Genotype and allele frequencies of different polymorphisms of COX-2, 5-LO, and
FLAP genes in 190 controls and 341 AD patients from Northern Italy
Locus Genotype/allele AD (N=341) Controls (N=190) P-value
GG 237 (69.5%) 115 (60.5%) 0.032*
−765 G/C GC 94 (27.5%) 62 (32.6%)
(COX-2) CC 10 (3%) 13 (6.9%)
G 568 (83.3%) 292 (76.8%) 0.03∗∗
C 114 (16.7%) 88 (23.2%)
GG 256 (75%) 159 (83.7%) 0.018∗
−1708G/A GA 77 (22.5%) 31 (16.3%)
(5-LO) AA 8 (2.5%) 0 (0)
G 589 (86.4%) 349 (91.8%) 0.007∗∗
A 93 (13.6%) 31 (8.2%)
GG 223 (65.4%) 137 (72%) 0.07∗
−1761G/A GA 112 (32.8%) 53 (28%)
(5-LO) AA 6 (1.8%) 0 (0)
G 558 (82%) 327 (86%) 0.07∗∗
A 124 (18%) 53 (14%)
GG 272 (80%) 146 (76.8%) 0.06∗
−336 G/A GA 62 (18%) 44 (23.2%)
(FLAP) AA 7 (2%) 0 (0)
G 606 (88.8%) 336 (88.4%) 0.08∗∗
A 76 (11.2%) 44 (11.6%)
∗The significance of the different genotype distribution between patients and con-
trols was calculated by chi-square test (3×2 table).
∗∗The significance of the different allele distribution between patients and controls
was calculated by chi-square test (2×2 table).
underrepresented in age-related controls. According
to genotype, a significant difference in the A allele
frequency between AD patients and controls was ob-
served. The A allele frequency was found to be higher
in patients than in controls. There were no significant
differences for genotype and allele frequencies in the
−1761G/A 5-LO and −336G/A FLAP SNPs between
patients and controls.
Gender analysis demonstrated that the significant
differences were not present by separately analyzing
male and female patients and controls (data not shown).
Comparing the genotypes and the alleles of −765G/C
COX-2 SNP and −1708G/A 5-LO SNP between the
two groups, the ORs for these genotypes and alleles
were statistically significant (Table 2).
In addition, we performed a logistic regression anal-
ysis to test the association of genotypes of −765G/C
COX-2 and −1708G/A 5-LO SNPs with AD after ad-
justment for the presence of ApoE4 allele, gender, and
age at onset. This analysis demonstrated that a sig-
nificant difference in genotype frequency of −765GG
COX-2 persisted between AD patients and controls
(p < 0.0001). In addition, using the same logistic re-
gression analysis, the difference in genotype frequency
of −1708AA 5-LO polymorphism persisted between
AD patients and controls (p < 0.0001). These results
indicate that the genotypes under study are independent
risk factors for developing AD in this population from
Northern Italy.
DISCUSSION
Inflammatory processes play a crucial role in the
pathophysiologyof AD. Many inflammatory mediators
have been detected in regions of the brain of patients
with AD and activation of astrocytes and microglial
cells causes expression of pro-inflammatory cytokines,
complement and acute phase proteins [2,3,41]. In par-
ticular, it has been demonstrated by recent findings that
COX-2 and 5-LO genes play a considerable role in AD
pathophysiology. In fact, COX-2 is largely expressed
in the AD patient brain; its expression correlates with
amyloid plaque density and neurofibrillary tangles [4,
7–10]. However, it has been suggested that COX-2 and
PG can play a role in AD pathophysiology that is not
dependent on an inflammatory pathway [20–22]. On
the other hand, epidemiological studies have suggested
that NSAIDs decrease the risk of developing AD [4,
14–17].
The finding of several polymorphisms in the pro-
moter region of COX-2 gene has suggested that the re-
duction of risk by COX inhibitors against AD may be
specific for particular genotypes [2], analogous to the
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Table 2
Odds ratio (OR) and confidence interval (CI) with P-value comparing
190 controls and 341 AD patients from Northern Italy
Controls P-value
AD (−765 GG COX-2) OR=1.48, 95% CI=1.025–2.15 0.044
AD (−765 G COX-2) OR=1.50, 95% CI=1.09–2.05 0.011
AD (−1708 AA 5-LO) OR=9.71, 95% CI=0.55–169.3 0.055
AD (−1708 A 5-LO) OR=1.77, 95% CI=1.15–2.72 0.007
observed protection against colorectal adenoma [42].
5-LO has been observed in neurons and in some glial
cells throughout the cerebrum, basal ganglia, and hip-
pocampus [5,27,28]. Compared to controls, a signifi-
cant increase of LTs was observed in cerebrospinal flu-
id from AD and mild cognitive impairment patients. So
the activation of this enzyme occurs early in the course
of AD [5,27,28].
The aim of our study was to evaluate whether the
COX-2 and 5-LO SNPs likely involved in different en-
zyme production can be considered risk factors for AD.
We found that the −765G of COX-2 and −1708A of
5-LO alleles were significantly higher in AD patients
and lower in age-related controls. This interpretation
is correct, i.e., these findings are related to an overrep-
resentation of reported alleles in AD but not to their
underrepresentation in the controls, as demonstrated by
the fact that these frequencies are not different from
those obtained in another Italian cohort and lower than
those obtained in Italian centenarians, i.e., a typical
example of successful ageing [43,44].
In addition, the stratification for ApoE4 allele, gen-
der, and age at onset clearly demonstrated that −765
G/A and −1708 G/A polymorphisms are risk factors
for AD independently of ApoE4, gender, and age at on-
set in Northern Italy population. Our findings confirm
and extend the data of a recent study which demonstrat-
ed that −765 COX-2 allele increases the risk for AD
independently of ApoE4 [24]. This is the first study
where the−1708G/A 5-LO SNP has been analyzed, so
it needs to be validated by further studies. A further
method of validation should be a meta-analysis that
provides a means to quantitatively synthesize associa-
tion data across studies of the same genetic variant. The
use of meta-analyses has recently become an important
part of genetic research mainly to reconcile previously
conducted studies that gave inconsistent results, but an
adequate number of studies is necessary [1,45].
In the present report, we have followed an ap-
proach known as candidate gene association, i.e., we
have selected the genes to be investigated according to
their known or postulated biology. Another approach,
genome-wide association (GWA), entails the screening
of the whole genome for associations. It investigates
hundreds of thousands of SNPs across the genome,
without any previous hypotheses about potential mech-
anisms or candidates. This kind of study has great-
ly accelerated the rate of detection of genetic associa-
tions. Testing so many potential genes simultaneously
carries the risk of finding many spurious associations.
On the other hand, the statistical correction performed
to avoid this type of error may be responsible for miss-
ing rare alleles with a low OR. Individual GWAs are
underpowered to detect all but the largest effects, and
the susceptibility variants identified so far are probably
only a subset of the loci that would be detectable using
this approach if power was increased [46,47]. Accord-
ingly, in 7 out 9 WGA studies performed until now,
as reported on the Alzforum website, the only repro-
ducible featured gene was APOE [48]. In any case,
polymorphisms involved in AD are fairly common in
the general population, so there is a strong likelihood
that any given individual will inherit one or more of the
high-risk alleles: the occurrence of the disease is like-
ly to depend on interaction between different high-risk
alleles, exposure to pathogens, environmental factors,
and lifestyle choices [2,3].
Finally, the differences between patients and controls
are significant but relatively small with unimpressive
ORs. However, since AD is a multifactorial disease,
any single mutation will only provide a small or modest
contribution to risk, also depending on interaction with
other genes and/or a particular environment [49].
These results might offer an approach to defining
individual risk profiles that can be applied to healthy
subjects to predict intrinsic risk of AD. Such risk pro-
files, when better established, can be used to trigger
further diagnostic procedures and early therapeutic in-
terventions aimed at preventing or significantly delay-
ing the clinical manifestations of AD. A customized
risk profile can also provide useful information for per-
sonalized therapeutics, i.e., for a pharmacogenomic ap-
proach [50]. The working hypothesis is that these poly-
morphisms might be a means to determine which AD
patients to treat with the inhibitors, and therefore the
possibility of preventive treatment with a specific in-
hibitor of eicosanoids or their enzymes [2,51].
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